An animal model is a non-human species used in biomedical research because it can mimic aspects of a biological process or disease found in humans.
Disease-to-target discovery is the process of identification and early validation of targets involved in a disease.
At IBT Bioservices, we specialize in providing comprehensive preclinical ELISA testing services to support research, drug development, and diagnostic applications. ELISA is a widely used immunoassay technique that allows for the detection and quantification of target analytes, such as proteins, antibodies, hormones, cytokines, and small molecules, with high sensitivity and specificity.
Serology testing is essential for evaluating the potential immune responses elicited by therapeutic proteins, biologics, and vaccines. We provide ELISA-based serology assays to detect and quantify the presence of anti-drug antibodies (ADAs) in biological samples. Our immunogenicity testing helps assess the immunogenic potential of therapeutic agents, identify potential adverse reactions, and support regulatory submissions.
ELISA can be utilized to determine the pharmacokinetic profiles of therapeutic agents in preclinical studies. We offer ELISA-based PK assays to measure drug concentrations in various matrices, including plasma, serum, and urine. Our PK studies provide critical data on drug absorption, distribution, metabolism, and elimination, helping to optimize dosing regimens and assess drug bioavailability.
ELISA-based cytokine profiling allows for the simultaneous measurement of multiple cytokines and growth factors in biological samples. We offer cytokine profiling panels tailored to specific research needs, enabling the comprehensive evaluation of immune responses, inflammation, and disease progression. Our cytokine profiling assays provide valuable insights into the complex interplay of cytokines and their roles in various physiological and pathological processes.
This assay tests for hemagglutinin (HA)-specific antibodies against influenza virus (INFV). Serial dilutions of the TA starting are incubated with a standardized amount of IFV antigen and Turkey Red Blood Cells (TRBCs) in 96-well plates. In the absence of antibodies against influenza hemagglutinin (HA) glycoprotein, the HA protein agglutinates TRBCs. Hemagglutination is inhibited in the presence of HA-specific antibodies, which will bind to the antigenic sites on the HA protein. The number of antibodies present in a sample is quantified as an HA titer, given as the highest dilution of serum that completely inhibits hemagglutination. IBT’s method is standardized to the WHO testing protocol and can use live virus for testing.
Our team of scientists and technicians are highly skilled and experienced in conducting HAI assays, ensuring accurate and reliable results.
We understand the unique needs of each research project and provide customized assay designs to meet your specific requirements.
We prioritize efficiency without compromising on quality. Our streamlined processes and advanced equipment allow for quick turnaround times, ensuring you receive results promptly.
We maintain rigorous quality control measures throughout our operations, ensuring the accuracy and reproducibility of our assay results.
Our dedicated customer support team is always available to address your queries and provide assistance at every step of the process.